Cortexin and citicoline in persistent postural-perceptual dizziness: three-group observation
N. A. Ivonina, K. B. Petrov · 2025 · Zh Nevrol Psikhiatr Im S S Korsakova. 2025;125(5):89–94. PMID 40457673
Indexed 2025-06-11.
Reported findings and study design
Narrative findings; numerical extraction incomplete
All groups reported less dizziness, anxiety and insomnia; the authors described the strongest changes with the combined adjuncts. The abstract does not provide numerical post-treatment group differences.
60 patients; 20 escitalopram plus Cortexin, 20 escitalopram plus Cortexin/citicoline, 20 escitalopram alone
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Dizziness, anxiety and insomnia | Improvement described in all three groups; strongest reported changes in the Cortexin/citicoline combination arm | No verified numerical post-treatment group contrast provided · End of treatment and two-month follow-up |
| Cohort and groups | 60 patients; three groups of 20; all received escitalopram | |
| Baseline symptom scores, not treatment effects | Vestibular balance 27.15±2.83; autonomic anxiety 16.05±2.35; insomnia 18.3±1.76 points | The repeated baseline value in the English follow-up sentence is not used as an endpoint · Before treatment |
| Adverse events | No event counts given in the checked abstract |
Baseline severity scores are not improvement estimates. The observational, multidrug comparison does not establish an isolated Cortexin benefit.
Source for the extracted data ↗ · Checked 2026-11-06
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- Observational allocation; no blinded placebo comparison established.
- All patients received escitalopram; the combination arm does not isolate Cortexin.
- The English abstract repeats a baseline vestibular score in its follow-up sentence. It is not treated as a verified post-treatment outcome.
- No numerical between-group effect, confidence interval or adverse-event count was available in the checked abstract.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Document format: Indexed original publication abstract
Review depth: Original indexed abstract and citation checked; full methods and tables not appraised
Source access and review scope
Original abstract retrieved through Europe PMC / PubMed. Publication year retained; index date is not the publication date.
Recorded source-check date: 2026-11-06. This date does not imply a completed systematic review.
Source type: Original clinical journal publication
Citation and original source
Original source: N. A. Ivonina, K. B. Petrov. Cortexin and citicoline in persistent postural-perceptual dizziness: three-group observation Zh Nevrol Psikhiatr Im S S Korsakova. 2025;125(5):89–94. PMID 40457673 2025.
Molekul research summary: https://molekul.io/research/cortexin-dizziness-2025. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry